SynCore Biotechnology Co Ltd (4192) — Cash Flow-to-Debt Ratio
SynCore Biotechnology Co Ltd (4192) has a Cash Flow-to-Debt Ratio of -0.48x as of September 2025, meaning its operating cash flow of NT$-7.18 Million could theoretically repay 0% of its total liabilities (NT$14.88 Million) in one year. See 4192 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SynCore Biotechnology Co Ltd Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for SynCore Biotechnology Co Ltd across 10 annual periods. For the full cash flow conversion analysis, see 4192 cash flow conversion.
Annual Cash Flow-to-Debt Ratio for SynCore Biotechnology Co Ltd (2015–2024)
Year-by-year debt coverage analysis for SynCore Biotechnology Co Ltd. Check SynCore Biotechnology Co Ltd (4192) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.13x | NT$-49.24 Million | NT$23.11 Million | ▲ +45.1% |
| 2023 | -3.88x | NT$-82.37 Million | NT$21.23 Million | ▼ -247.4% |
| 2022 | -1.12x | NT$-209.61 Million | NT$187.64 Million | ▼ -85.4% |
| 2021 | -0.60x | NT$-229.86 Million | NT$381.52 Million | ▲ +32.8% |
| 2020 | -0.90x | NT$-316.63 Million | NT$353.41 Million | ▲ +67.5% |
| 2019 | -2.76x | NT$-418.57 Million | NT$151.84 Million | ▲ +0.7% |
| 2018 | -2.78x | NT$-272.26 Million | NT$98.11 Million | ▼ -72.1% |
| 2017 | -1.61x | NT$-201.96 Million | NT$125.28 Million | ▼ -22.7% |
| 2016 | -1.31x | NT$-195.09 Million | NT$148.46 Million | ▼ -55.4% |
| 2015 | -0.85x | NT$-156.03 Million | NT$184.46 Million | — |